Introduction: Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide
Methods: Canagliflozin, at doses of 25, 100, 200, or 400 mg, was administered as a single dose and, after a washout of 1 day, in repeated doses for 14 consecutive days to 61 subjects in a randomized, double-blind, placebo-controlled study. Plasma concentrations of canagliflozin and urinary glucose excretion (UGE) were measured, and renal threshold for glucose excretion (RT G ) was calculated. Safety was evaluated on the basis of adverse event (AE) reports, blood and urine laboratory parameters, and vital signs. 
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is caused by insufficient insulin action due to increased insulin resistance and/or impaired insulin secretion. In addition to these mechanisms, the role of kidney function in glycemic control has been noted. In the kidney, approximately 90% of filtered glucose is reabsorbed by the sodium glucose co-transporter (SGLT) 2 in the S1 segment of proximal tubules, and the residual glucose is reabsorbed by SGLT1 in the S2 and S3 segments [1] . These transporters reabsorb filtered glucose almost completely until the filtered load exceeds the transport capacity; the plasma glucose (PG) concentration at which this occurs is designated the renal threshold for glucose (RT G ). In patients with T2DM, RT G is higher than that in nondiabetic individuals [1, 2] .
The pharmacological inhibition of SGLT2 lowers RT G through the suppression of glucose reabsorption in the proximal tubules and exerts antihyperglycemic effects by inducing urinary glucose excretion (UGE). Thus, SGLT2 inhibitors reduce PG levels in an insulin-independent manner and also promote weight reduction by excreting the ingested calories in the form of glucose [3, 4] . Furthermore, some SGLT2 inhibitors have shown antihypertensive effects because of their diuretic action [5, 6] . In addition to blood glucose control, the management of body weight and blood pressure is critical for the prevention of diabetic complications [7, 8] .
Therefore, SGLT2 inhibitors may offer a novel option for the treatment of T2DM. On the other hand, increased hematocrit level and transient dehydration after the administration of SGLT2 inhibitors have been reported [6, 9, 10] , whereas the changes in parameters related to body fluid volume after drug administration have not been investigated in detail in Japanese patients with T2DM.
Canagliflozin is an SGLT2 inhibitor available for the treatment of T2DM in many countries, including Japan [11] [12] [13] [14] [15] [16] [17] [18] . In the United States, a clinical study was conducted on the tolerability and dose-dependent pharmacokinetics and pharmacodynamics of canagliflozin at doses of 50-300 mg in healthy subjects or patients with T2DM [19, 20] . We previously reported the pharmacodynamic profiles of canagliflozin in Japanese patients with T2DM and moderate renal impairment in an open-label, cross-over study [14] . In the present study, we evaluated the pharmacokinetics, pharmacodynamics, and safety-including parameters related to body fluid volume-of canagliflozin in Japanese patients with T2DM. 
METHODS

Patients
Study Design, Treatments and Blinding
The study design is shown in Fig. 1a . This randomized, double-blind, placebo-controlled, multiple-dose, phase 1 study was conducted at four study centers in Japan. This study consisted of a washout period of 12 
Sampling and Analysis
Pharmacokinetic parameters were assessed using venous blood samples at different time and 24-h mean serum insulin.
Changes from baseline in UGE were assessed on Days 0, 1, 2, 3, 4, 5, 6, 15, 16, 17, and 18. The RT G on Days 0, 1, and 16 was calculated post hoc from the measured PG, UGE, and estimated glomerular filtration rate as previously described [18, 21, 22] . HbA1c values were measured with the Japan Diabetic Society (JDS) method during the study. As JDS issued a recommendation to use HbA1c (NGSP) instead of HbA1c (JDS) after study completion [23] , HbA1c (JDS) values were converted to HbA1c (NGSP) in the present report.
Safety Assessments
Adverse events (AEs) were classified according to the system organ class and preferred terms of the Medical Dictionary for Regulatory Activity (MeDRA/J version 11.1). In addition, volume-related safety was assessed with changes in blood and urinary laboratory parameters and vital signs, including blood pressure, pulse rate, and body temperature.
Statistical Analysis
For sample size determination, the number of subjects was set at 15 (12 receiving canagliflozin and 3 receiving placebo) for each step to evaluate pharmacokinetics, pharmacodynamics, and safety of canagliflozin administered as single and 14-day multiple doses. As reference, assuming that the percentage change in MPG 0-24h on Day 16 relative to the day of placebo administration is comparable to that obtained in the clinical studies conducted in other countries, the probability of detecting a difference between the highest dose (400 mg) treatment and placebo was 99%, whereas the probability of detecting a difference between the 200-mg treatment and placebo was 96% (two-sided test with a significance level of 5%).
Safety analyses were performed in all patients who received C1 dose of the study drug.
Pharmacokinetic and pharmacodynamic analyses were conducted in the subsets of subjects in the safety analysis set who were evaluable for the pharmacokinetic and pharmacodynamic assessments, respectively.
For the pharmacokinetic analysis, WinNonlin ver.5.2, Pharsight, Mountain View, CA, USA) was used; for all other analysis, SAS Ò ver. 9.1.3 (SAS Institute Inc., Cary, NC, USA) was used.
RESULTS
Patient Disposition and Baseline Characteristics
A total of 61 patients (50 men and 11 women)
were randomized to receive canagliflozin (n = 51) or placebo (n = 10) in the study (Fig. 1b) . (Table 2) .
Pharmacodynamic Effects
The mean UGE 0-24h values were approximately 14-24 g on Day 0 and markedly increased after the administration of canagliflozin at 25, 100, 200, or 400 mg compared with baseline, whereas no increase was observed in UGE 0-24h after placebo administration. The mean change from baseline in UGE 0-24h values on Day 1 was approximately 60 g/day in the 25-mg group and ranged from 80 to 110 g/day with no great difference in the 100-400-mg groups (Fig. 3a) .
Similar increases from baseline in UGE 0-24h were observed on Day 16, indicating that the increase in UGE because of canagliflozin is sustained during repeated-dose administration. The increase in UGE was detected during and 48-72 h after the last administration of canagliflozin at C100 mg. There was no increase in UGE 0-24h during placebo administration.
The mean baseline RT G0-24h values on Day 0 ranged from 210 to 250 mg/dL in the canagliflozin and placebo groups, which were higher than those in healthy adults (*200 mg/ dL) [1] . The RT G0-24h decreased after the administration of canagliflozin on both Days 1 and 16 (Fig. 3b) Fig. 4 Effects of canagliflozin on the changes from baseline in urinary volume (a), water intake (b), and urinary sodium excretion (c). Data are mean ± standard deviation did not markedly change during this period (Fig. 4b) . No remarkable changes were observed in the urinary excretion of electrolytes, including potassium, chloride, calcium, magnesium, and inorganic phosphorus, but not sodium, in canagliflozin-treated groups compared with the placebo group (see Table S2 in the Electronic Supplementary Material). A transient nominal increase of sodium was observed on Day 1, although this increase reversed within a week (Fig. 4c) . The change in hourly urine volume over time from baseline on Day 1 is shown in Fig. 5a . The hourly urine volume was slightly increased in canagliflozin-treated groups compared with the placebo group up to 10.5-13 h, whereas no difference was seen at the 13-24-h time period.
The changes in hourly urinary sodium excretion from baseline on Day 1 showed similar time profiles as those for hourly urine volume (Fig. 5b) . The change in urine osmolality over time from baseline on Day 1 showed a trend toward an increase in the canagliflozin-treated groups, whereas no change in osmolality was observed in the placebo group (Fig. 5c) . The increase in urine osmolality was sustained up to Day 16 in canagliflozin-treated groups consistent with the persistent increase in UGE (data not shown). On the other hand, serum osmolality was maintained constant during the treatment period in all study groups (Fig. 6a) . The hematocrit level was similar between the canagliflozin and placebo groups at baseline and remained unchanged during the study period (Fig. 6b) . Mean systolic and diastolic blood pressures tended to decrease in groups that received canagliflozin C100 mg (see clearance were observed after multiple doses at all dose levels. These pharmacokinetic profiles of canagliflozin in Japanese patients were similar to those previously reported in non-Japanese patients [19, 20] .
Renal glucose reabsorption was rapidly inhibited, and RT G was decreased after canagliflozin administration on Days 1 and 16.
A near-maximal RT G -lowering effect was induced in the 100-mg group. The RT G -lowering effects of canagliflozin were not diminished by repeated administration. UGE was markedly increased in all canagliflozin-treated groups. The change in UGE 0-24h from baseline was smallest in the 25-mg group, and ranged from 80 to 110 g/day with no great difference in the 100-400-mg groups. Collectively, it is noted that canagliflozin exerts near-maximal efficacy at a dose of 100 mg in Japanese patients with T2DM. The increase in UGE was sustained during repeated-dose administration. The decrease in both MPG 0-24h and FPG after single and repeated doses was greater in the canagliflozin groups than in the placebo group. These pharmacodynamic profiles of canagliflozin in Japanese patients were also similar to those in studies with non-Japanese patients [3, 20, 22, 24] . In the current short-term study, canagliflozin was well tolerated in patients with T2DM, with a low incidence of AEs. Urinary ketones were observed in 3 patients in canagliflozin-treated groups; 2 cases at a dose of 200 mg and 1 case at a dose of 400 mg. All cases were mild and rapidly returned to a negative level without signs and symptoms of ketoacidosis. It is recommended that patients taking SGLT2 inhibitors should be assessed for ketoacidosis when they present with signs and symptoms of metabolic acidosis to prevent delayed diagnosis and management [25, 26] . We then assessed any influences on urine volume, urine electrolytes, hematocrit, and 
CONCLUSIONS
In Japanese patients with T2DM in the present study, the pharmacokinetic profiles of canagliflozin were similar to those in non-Japanese patients. The maximal pharmacodynamic effect was exerted at canagliflozin doses C100 mg, and it was well tolerated in this population.
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